The BDP was established in 1993. We support the development of monoclonal antibodies, recombinant proteins, therapeutic peptides and DNA vaccines, virus therapeutics and vaccines, gene therapy products, and other biological agents. Since its inception BDP has completed more than 100 projects. The program has released over 220 lots of different products since 1997 and more than 60 agents have gone into human clinical trials.

Our facilities are designed to be flexible, enabling us to work on multiple projects for a variety of different indications. The BDP provides a unique NCI-funded resource which differentiates it from other biopharmaceutical development programs: we concentrate on products that are in early development, beginning with demonstrating product feasibility on the bench through producing Phase I/II clinical supplies for first-in-human clinical trials.

The BDP makes available over 300 documents that are useful for any investigator, company or group developing biopharmaceuticals. These documents can help scientific, clinical manufacturing, quality control and quality assurance professionals. You can request electronic copies of these BDP documents by clicking on the button below.

Occasionally academia and other government agencies use the BDP for training.